Viridian Therapeutics Stock Probability of Future Stock Price Finishing Over 27.90
| VRDN Stock | USD 27.90 0.85 2.96% |
Closest to current price Viridian long PUT Option Payoff at Expiration
Viridian Therapeutics Target Price Odds to finish over 27.90
The tendency of Viridian Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 27.90 | 90 days | 27.90 | about 98.0 |
Based on a normal probability distribution, the odds of Viridian Therapeutics to move above the current price in 90 days from now is about 98.0 (This Viridian Therapeutics probability density function shows the probability of Viridian Stock to fall within a particular range of prices over 90 days) .
Viridian Therapeutics Price Density |
| Price |
Predictive Modules for Viridian Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Viridian Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Viridian Therapeutics is not an exception. The market had few large corrections towards the Viridian Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Viridian Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Viridian Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.01 | |
β | Beta against Dow Jones | 0.68 | |
σ | Overall volatility | 1.61 | |
Ir | Information ratio | -0.01 |
Viridian Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Viridian Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Viridian Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Viridian Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (247.39 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Viridian Therapeutics, Inc. Stock Analysis 42 percent Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews |
Viridian Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Viridian Stock often depends not only on the future outlook of the current and potential Viridian Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Viridian Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 67.9 M | |
| Cash And Short Term Investments | 717.6 M |
Viridian Therapeutics Technical Analysis
Viridian Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Viridian Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Viridian Therapeutics. In general, you should focus on analyzing Viridian Stock price patterns and their correlations with different microeconomic environments and drivers.
Viridian Therapeutics Predictive Forecast Models
Viridian Therapeutics' time-series forecasting models is one of many Viridian Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Viridian Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Viridian Therapeutics
Checking the ongoing alerts about Viridian Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Viridian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Viridian Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (247.39 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Viridian Therapeutics, Inc. Stock Analysis 42 percent Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews |
Check out Viridian Therapeutics Analysis, Viridian Therapeutics Valuation, Viridian Therapeutics Correlation, Viridian Therapeutics Hype Analysis, Viridian Therapeutics Volatility, Viridian Therapeutics Price History as well as Viridian Therapeutics Performance. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value - what Viridian Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.